1009-80-9 Usage
General Description
Methyl 3-(morpholin-4-yl)prop-2-enoate is a chemical compound with the molecular formula C9H15NO3. It is a type of ester, specifically an acrylate ester, consisting of a methyl group, a morpholine ring, and an acrylate group. methyl 3-(morpholin-4-yl)prop-2-enoate is commonly used in the synthesis of various pharmaceuticals, agrochemicals, and materials. It is known for its ability to act as a versatile building block in organic synthesis, and it is often utilized in the production of polymers and other advanced materials. Additionally, it has applications in the development of highly efficient catalysts and as an intermediate in the synthesis of various bioactive compounds. Overall, methyl 3-(morpholin-4-yl)prop-2-enoate is a valuable compound with diverse uses in the chemical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1009-80-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,0,0 and 9 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1009-80:
(6*1)+(5*0)+(4*0)+(3*9)+(2*8)+(1*0)=49
49 % 10 = 9
So 1009-80-9 is a valid CAS Registry Number.
1009-80-9Relevant articles and documents
Diastereoselective synthesis of functionalized tetrahydropyrimidin-2- thiones via ZnCl2 promoted one-pot reactions
Liu, Zhenming,Zhang, Lili,Sun, Jing,Yan, Chaoguo
, p. 172 - 178 (2014)
In the presence of zinc chloride, the in situ generated β-enamino ester from the reaction of morpholine, piperidine and pyrrolidine with methyl propiolate reacted, with aromatic aldehydes and thiourea in ethanol resulting in the functionalized tetrahydrop
CINNOLINES AS INHIBITORS OF HPK 1
-
Page/Page column 49-50, (2021/01/29)
Compounds of Formula (I) or (Ia), pharmaceutically acceptable salts, stereoisomers, tautomers, solvates or prodrugs, and their use as HPK1 inhibitors are described herein, and also described are methods for preparing the compounds, and methods of treating HPK1-dependent diseases or disorders, such as cancer.
